Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate for long-term ICU sedation (≥72h)
CTR20233092Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remimazolam in Sedation requirement, sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Oct 2023; status: completed.
02
Drugs
remimazolam
03
Conditions
Sedation requirement
Beyond the preview
Go deeper on CTR20233092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233092.